Advertisement
Advertisement
-
Money /

Money News

Related Topics:
Banking & finance
Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

Advertisement
Advertisement
Advertisement
IPO

Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong

The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.

Unisplendour was expected to raise US$1 billion from its Hong Kong share sale this year. Photo: Reuters
Unisplendour was expected to raise US$1 billion from its Hong Kong share sale this year. Photo: Reuters
Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

An employee works on a drug production line at a pharmaceutical company in Meishan, China, on January 30, 2024. Photo: NurPhoto via Getty Images
Banking & finance

China slashes wait times for loss-making tech firms seeking refinancing, fundraising

Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.

videocam
People walk past the Shanghai Stock Exchange Building in Shanghai, China. Photo: EPA-EFE
People walk past the Shanghai Stock Exchange Building in Shanghai, China. Photo: EPA-EFE
Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Banking & finance

Chinese gold, silver investors face gut check amid volatility, fund suspensions

Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.

A saleswoman adjusts gold jewellery for sale at a shop in Lianyungang, in China’s eastern Jiangsu province, on December 24, 2025. Photo: AFP
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Advertisement
Advertisement
Advertisement
Banking & finance

SF Holding, J&T strike US$1 billion deal as Asian e-commerce booms

The agreement will help SF Holding expand its international businesses, according to the Shenzhen-based company.

The deal will see SF Holding acquire an 8.45 per cent stake in J&T for about HK$8.3 billion. Photo: Shutterstock Images
The deal will see SF Holding acquire an 8.45 per cent stake in J&T for about HK$8.3 billion. Photo: Shutterstock Images
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Banking & finance

TCM firms eye Hong Kong IPOs to fuel global expansion

Over the past year, 34 innovation and technology, life and health science companies set up or expanded their operations in Hong Kong.

A traditional Chinese medicine pharmacy at the Hong Kong Chinese Medicine Hospital in Tseung Kwan O. Photo: Edmond So
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Banking & finance

Citic Securities claims top spot in Asia-Pacific investment banking for 2025

Chinese rivals fill out the rest of the top five, while US bank Morgan Stanley comes in sixth.

Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW